THR. Oxurion NV

Oxurion Receives EUR 450,000 in the framework of the Atlas Funding Program : Eleventh tranche fully issued and paid-up

Oxurion Receives EUR 450,000 in the framework of the Atlas Funding Program : Eleventh tranche fully issued and paid-up

Oxurion Receives EUR 450,000 in the framework of the Atlas Funding Program

Eleventh tranche fully issued and paid-up

Leuven, BELGIUM, 10 April 2024 – 07.00 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company based in Leuven, today communicates it has received an aggregate amount of EUR 450,000 in the framework of the Atlas Funding Program.

On April 10, 2024, the Company issued the Eleventh Tranche consisting of 18 convertible bonds, for an aggregate amount of EUR 450,000.

This tranche has been issued in accordance with the agreement reached with Atlas end of 2023, as further described in the press release issued by the Company on December 28, 2023.

About Oxurion

Oxurion (Euronext Brussels: OXUR) is engaged in developing next-generation standard of care ophthalmic therapies for the treatment of retinal disease. Oxurion is based in Leuven, Belgium. More information is available at .

Please contact for additional information:

Oxurion NV

Pascal Ghoson

Chief Executive Officer





 		Backstage Communication

Jurgen Vluijmans

Partner





 

Attachments



EN
10/04/2024

Underlying

THR.Oxurion NV

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Oxurion NV

 PRESS RELEASE
Free
THR. OXURION NV

Oxurion Share Consolidation

Oxurion Share Consolidation Oxurion Share Consolidation Leuven, BELGIUM – July 25, 2024 – 06:00 PM CET (Euronext Brussels: OXUR) (the Company), a biopharmaceutical company based in Leuven, announced today that its Board of Directors, authorized by the General Meeting of July 24, 2024, will proceed with a consolidation of all existing shares. This consolidation will be carried out at a ratio of one (1) new share for ten thousand (10,000) existing shares. This share consolidation is a strategic step to increase the nominal value of the shares, simplify the capital structure, and improve th...

July 25, 2024 1 EN
 PRESS RELEASE
Free
THR. OXURION NV

Oxurion Announces Results on the Extraordinary General Meeting (EGM) o...

Oxurion Announces Results on the Extraordinary General Meeting (EGM) of 24 July 2024 Oxurion Announces Results on the Extraordinary General Meeting (EGM) of 24 July 2024 Leuven, BELGIUM – 24 July, 2024 – 06.00 PM CET – (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, held an Extraordinary General Meeting on July 24, 2024. The shareholders approved all items on the agenda of the Extraordinary General Meeting. All documents pertaining to the Extraordinary General Meeting held on July 24, 2024, can be consulted on Oxurion’s website . About Oxurion Oxur...

July 24, 2024 1 EN
 PRESS RELEASE
Free
THR. OXURION NV

Information on the Total Number of Voting Rights (Denominator) followi...

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100,000 capital increase. This is part of Atlas Special Opportunities, LLC’s EUR 20 million Capital Commitment1 that will allow Oxurion to focus on developing innovative therapeutics to preserve the vision of elderly people, targeting potential market opportunities of USD 3-6 billion. Leuven, ...

July 19, 2024 1 EN
 PRESS RELEASE
Free
THR. OXURION NV

Oxurion Receives Transparency Notification from Atlas Special Opportun...

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Leuven, BELGIUM – July 18, 2024 – 06:00 PM CET - (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows: Oxurion received a transparency notification on July 17, 2024, from Atlas Special Opportunities, LLC indicating that as of July 17, 2024, it held 941,611,204 shares of the then o...

July 18, 2024 1 EN
 PRESS RELEASE
Free
THR. OXURION NV

Oxurion provides clarification on the agenda of the extraordinary gene...

Oxurion provides clarification on the agenda of the extraordinary general shareholders' meeting to be held on 24 July 2024 Oxurion provides clarification on the agenda of the extraordinary general shareholders' meeting to be held on 24 July 2024 Leuven, BELGIUM – July 11, 2024 – 6:00pm CET – Oxurion NV (Euronext Brussels: OXUR), an innovative biopharmaceutical company based in Leuven, announced today it has provided clarification on the agenda of the extraordinary general shareholders' meeting to be held on 24 July 2024 (the EGM) as set out in the convening notice published on 5 July 2024 ...

July 11, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch